Self-micellizing fatty acids and fatty acid ester compositions and their use in the treatment of disease states
Described herein are compositions including at least one omega-3 fatty acid (either in the triglyceride, ester or free fatty acid ester form) and at least one surface active agent; wherein the compositions form micelles when in contact with an aqueous medium. Also provided are methods of administering to a subject a composition including at least one omega-3 fatty acid (either in the triglyceride, ester or free fatty acid ester form) and at least one surface active agent, wherein the compositions form micelles when in contact with an aqueous medium, and the bioavailability of the omega-3 fatty acid is substantially independent of a food effect. The compositions are useful for treating certain disease states which may include (1) malabsorption syndromes, (2) primary sclerosing cholangitis (PSC), (3) non-alcoholic fatty liver disease (NAFLD), (4) sickle cell disease (SCD), (5) age-related macular degeneration (AMD), and (6) neurodegenerative disease, including, Parkinson's Disease (PD), Alzheimer's Disease (AD), Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's Disease), Epilepsy, Bi-polar Syndrome, traumatic brain injury, peripheral neuropathy, and Multiple Sclerosis (MS). Described are also various dosage forms for administering the compositions and use of the compositions in functional foods. Provided herein are also kits with instructions for their administration.
1. A pharmaceutical composition comprising:
artificially formed micelles formed upon contact with an aqueous solution, the micelles comprising at least one omega-3 fatty acid and at least one surface active agent, and providing for absorption of omega-3 fatty acid esters substantially free of any food effect;
wherein said at least one surface active agent comprises a combination of at least one polysorbate and at least one poloxamer,
wherein said at least one polysorbate comprises from about 30.0% wt/wt to about 32.0% wt/wt of said composition,
wherein said at least one poloxamer comprises from about 0.60% wt/wt to about 0.80% wt/wt of said composition,
wherein said at least one polysorbate is polyoxyethylene (20) sorbitan monooleate (polysorbate 80), and
wherein said at least one poloxamer is a block copolymer of polyethylene glycol and polypropylene glycol having the formula [(HO(C 2 H 4 O) 64 (C 3 H 6 O) 37 (C 2 H 4 O) 64 H] (Poloxamer 237).
2. The pharmaceutical composition according to claim 1 , wherein said at least one omega-3 fatty acid comprises at least about 40.0% (wt/wt) of the composition.
3. The pharmaceutical composition according to claim 1 , wherein said at least one polysorbate comprises about 31.0% (wt/wt) of the composition.
4. The pharmaceutical composition according to claim 1 , wherein said at least one poloxamer comprises about 0.70% (wt/wt) of the composition.
5. The pharmaceutical composition according to claim 1 , wherein said at least one omega-3 fatty acid is a triglyceride, an ester or a free fatty acid.
6. The pharmaceutical composition according to claim 1 , wherein said at least one omega-3 fatty acid is docosahexaenoic acid (DHA), eicosapentaenoic acid (EPA), or a combination of both DHA and EPA.
7. The pharmaceutical composition according to claim 1 , wherein said composition further comprises a non-omega-3 fatty acid active agent.
8. The pharmaceutical composition according to claim 7 , wherein said non-omega-3 fatty acid active agent is arachidonic acid (AA), a nutritional supplement, a statin, an antioxidant, or any combination thereof.
9. The pharmaceutical composition according to claim 8 , wherein said non-omega-3 fatty acid nutritional supplement is folic acid, vitamin C, vitamin E, betacarotene, magnesium, manganese, calcium, vitamin A, vitamin D, vitamin K1, vitamin K2, lutein, zeaxanthin, a zinc, a copper, or any combination thereof.
10. The pharmaceutical composition according to claim 1 , wherein the antioxidant comprises tocopherol, tocotrienol, or a combination of both.
11. The pharmaceutical composition according to claim 1 , wherein said micelles are from about 1.0 to 10.0 microns in size.
12. The pharmaceutical composition according to claim 1 , wherein said omega 3 fatty acid is EPA,
wherein said at least one polysorbate comprises about 31.0% (wt/wt) of the composition, and
wherein said at least one poloxamer comprises about 0.70% (wt/wt) of the composition.
13. The pharmaceutical composition according to claim 1 , wherein said EPA comprises at least about 40% (wt/wt) of the composition.
14. The pharmaceutical composition according to claim 1 , wherein said omega 3 fatty acid is DPA, wherein said at least one polysorbate comprises about 31.0% (wt/wt) of the composition, and wherein said at least one poloxamer comprises about 0.70% (wt/wt) of the composition.
15. The pharmaceutical composition according to claim 1 , wherein the pharmaceutical composition has a therapeutic bioavailability of the omega-3 fatty acid that is substantially equivalent when administered with or without food.
16. The pharmaceutical composition according to claim 1 , wherein said micelles are spontaneously formed in aqueous solution without agitation.
17. The pharmaceutical composition according to claim 1 for use in treating or preventing a malabsorption syndrome.
18. The pharmaceutical composition according claim 1 for use in treating or preventing sickle cell disease or disease symptoms.
19. A pharmaceutical composition comprising:
at least 90% pure docosahexaenoic acid (DHA); and
at least one surface active agent comprising a combination of:
polyoxyethylene (20) sorbitan monooleate (polysorbate 80) present from about 30.0% wt/wt to about 32.0% wt/wt of the composition, and
a block copolymer of polyethylene glycol and polypropylene glycol having the formula [(HO(C 2 H 4 O) 64 (C 3 H 6 O) 37 (C 2 H 4 O) 64 H] (Poloxamer 237) present from about 0.60% wt/wt to about 0.80% wt/wt of said composition,
wherein the composition artificially forms micelles upon contact with an aqueous solution, and the artificially formed micelles provide for absorption of the DHA substantially free of any food effect.
20. A micelle formed from a composition according to claim 1 .